ライフサイエンスコーパス: hematopoietic stem cell transplant

1 tory viral infections occur frequently after hematopoietic stem cell transplant.

2 with posaconazole without recurrence after a hematopoietic stem cell transplant.

3 n volunteer donors for patients in need of a hematopoietic stem cell transplant.

4 of herpes zoster infection in recipients of hematopoietic stem cell transplant.

5 es zoster infections in the first year after hematopoietic stem cell transplant.

6 tion of the TBI dose used in matched sibling hematopoietic stem cell transplant.

7 e pioneered by the development of allogeneic hematopoietic stem cell transplant.

8 T-cell reconstitution after unrelated-donor hematopoietic stem cell transplant.

9 ial morbidity and mortality after allogeneic hematopoietic stem cell transplant.

10 ant morbidity and mortality after allogeneic hematopoietic stem cell transplant.

11 of infection with one of these viruses after hematopoietic stem cell transplant.

12 ntribute to stable engraftment of allogeneic hematopoietic stem cell transplants.

13 lem in the long-term survivors of allogeneic hematopoietic stem cell transplants.

14 yeloid leukemia who had undergone autologous hematopoietic stem-cell transplant 50 to 70 days earlier

15 n the management of myeloablative allogeneic hematopoietic stem cell transplants, airflow obstruction

16 rt, 31% of those starting treatment achieved hematopoietic stem cell transplant (alloHSCT) compared w

17 ) remains a major complication of allogeneic hematopoietic stem cell transplant (alloHSCT), underscor

18 ional trial of 120 consecutive recipients of hematopoietic stem cell transplant and a multivariate an

19 ilitated development of new nonmyeloablative hematopoietic stem cell transplant and gene therapy appr

20 ping from CLL patients in need of allogeneic hematopoietic stem cell transplant and has recruited mil

21 mong non-AL patients (P = .005 vs allogeneic hematopoietic stem cell transplant and P = .048 vs other

22 Fungal infections that occur after hematopoietic stem cell transplant and therapies for hem

23 tem cell transplant, persons with autologous hematopoietic stem cell transplant and those without gra

24 tients undergoing dose-intensive therapy and hematopoietic stem cell transplant and to examine the as

25 treatment strategies such as unrelated donor hematopoietic stem cell transplant and tyrosine kinase i

26 Four of the children received hematopoietic stem cell transplants and all showed poor

27 ous chemokines, and biologic therapy such as hematopoietic stem cell transplants and mesenchymal cell

28 nic erythrocyte transfusions, bone marrow or hematopoietic stem cell transplants, and experimental ph

29 Recipients of allogeneic hematopoietic stem cell transplant appear to have the hi

30 e clinical efficacy for both solid organ and hematopoietic stem cell transplant applications.

31 n be realized in the field of hematology, as hematopoietic stem cell transplants are already commonpl

32 atus but not positron emission tomography or hematopoietic stem cell transplant as independent progno

33 evere combined immunodeficiency who received hematopoietic stem-cell transplants at Duke University M

34 days of HSC transplantation in 22 autologous hematopoietic stem cell transplant (auto-HSCT) and 25 al

35 aftment and subsequent admissions with a non-hematopoietic stem cell transplant cohort and excluded s

36 The unadjusted mortality was 32.9% in non-hematopoietic stem cell transplant cohort, which was sim

37 five times higher when compared with the non-hematopoietic stem cell transplant cohort.

38 ents receive myeloablative chemotherapy with hematopoietic stem-cell transplant followed by adjuvant

39 hed transplantation provides the benefits of hematopoietic stem cell transplant for nearly all patien

40 a in a 2-year-old female patient following a hematopoietic stem cell transplant for relapsed acute ly

41 -versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplant from a human histocom

42 choice for ADA-deficient SCID (ADA-SCID) is hematopoietic stem cell transplant from an HLA-matched s

43 even hundred fifty-two patients who received hematopoietic stem cell transplants from 2004 through 20

44 splantation in HLA-C2 positive recipients of hematopoietic stem cell transplants from 2DS1 positive d

45 tial as ex vivo purging agents of autologous hematopoietic stem cell transplants from CML patients.

46 for 1277 patients with AML who had received hematopoietic stem-cell transplants from unrelated donor

47 tution in patients undergoing haploidentical hematopoietic stem cell transplant (haplo-HSCT) without

48 Allogeneic hematopoietic stem cell transplant (hazard ratio [HR] =

49 immunogenicity results of MVA in allogeneic hematopoietic stem cell transplant (HCT) recipients and

50 is widely used as a surveillance method for hematopoietic stem cell transplant (HCT) recipients.

51 needs in the fields of both solid-organ and hematopoietic stem cell transplant (HCT).

52 y virus (HIV) with CD4(+) </=200; autologous hematopoietic stem-cell transplant (HCT) or allogeneic-H

53 ase was examined in 3 consecutive cohorts of hematopoietic stem-cell transplant (HCT) recipients (n=2

54 lity of life (QOL) and symptom burden during hematopoietic stem-cell transplant (HCT).

55 ceiving chemotherapy and a majority received hematopoietic stem cell transplant (HSCT) (11/13).

56 Autologous hematopoietic stem cell transplant (HSCT) has been effec

57 The field of hematopoietic stem cell transplant (HSCT) has made groun

58 Acute lung injury (ALI) during hematopoietic stem cell transplant (HSCT) is associated

59 Hematopoietic stem cell transplant (HSCT) is the only cu

60 Autologous and allogeneic hematopoietic stem cell transplant (HSCT) patients are s

61 Hematopoietic stem cell transplant (HSCT) patients contr

62 (CMV) retinitis in the pediatric allogeneic hematopoietic stem cell transplant (HSCT) population is

63 tive donor for a CMV-seronegative allogeneic hematopoietic stem cell transplant (HSCT) recipient is g

64 Hematopoietic stem cell transplant (HSCT) recipients adm

65 Cytomegalovirus (CMV) viral loads in hematopoietic stem cell transplant (HSCT) recipients are

66 stengraftment invasive aspergillosis (IA) in hematopoietic stem cell transplant (HSCT) recipients inc

67 in the context of adoptive immunotherapy for hematopoietic stem cell transplant (HSCT) recipients or

68 t al report a phase 2 study in 50 allogeneic hematopoietic stem cell transplant (HSCT) recipients who

69 ratory virus detected in >/=9% of allogeneic hematopoietic stem cell transplant (HSCT) recipients, in

70 among both solid organ transplant (SOT) and hematopoietic stem cell transplant (HSCT) recipients.

71 red as a cause of infection in azole-treated hematopoietic stem cell transplant (HSCT) recipients.

72 ity and mortality, particularly in pediatric hematopoietic stem cell transplant (HSCT) recipients.

73 virus-associated infectious complications in hematopoietic stem cell transplant (HSCT) recipients.

74 nocompromised patients, including allogeneic hematopoietic stem cell transplant (HSCT) recipients.

75 f morbidity and mortality in solid organ and hematopoietic stem cell transplant (HSCT) recipients.

76 in hematological patients and especially in hematopoietic stem cell transplant (HSCT) recipients.

77 s susceptible to latency and reactivation in hematopoietic stem cell transplant (HSCT) recipients.

78 ses of morbidity and mortality in allogeneic hematopoietic stem cell transplant (HSCT) recipients.

79 suppressive therapy, such as solid organ and hematopoietic stem cell transplant (HSCT) recipients.

80 and mortality in patients with leukemia and hematopoietic stem cell transplant (HSCT) recipients.

81 ipheral blood mononuclear cells (PBMCs) from hematopoietic stem cell transplant (HSCT) recipients.

82 rituximab-based treatment in the allogeneic hematopoietic stem cell transplant (HSCT) setting.

83 Hematopoietic stem cell transplant (HSCT)-associated thr

84 sed morbidity and mortality after allogeneic hematopoietic stem cell transplant (HSCT).

85 ections (RVIs) are frequent complications of hematopoietic stem cell transplant (HSCT).

86 s are of particular interest in the field of hematopoietic stem cell transplant (HSCT).

87 rising after solid organ transplant (SOT) or hematopoietic stem cell transplant (HSCT).

88 survival and stabilize cerebral disease is a hematopoietic stem cell transplant (HSCT).

89 HLA-matched related or unrelated allogeneic hematopoietic stem cell transplant (HSCT).

90 ter undergoing a double umbilical cord blood hematopoietic stem cell transplant (HSCT).

91 hromatic leukodystrophy after treatment with hematopoietic stem cell transplant (HSCT).

92 apies are available other than myeloablative hematopoietic stem cell transplant (HSCT); however, rela

93 ccus pneumoniae infections often occur after hematopoietic stem cell transplant (HSCT); vaccination i

94 s higher in patients receiving an allogeneic hematopoietic stem cell transplant (HSCT, 79%) versus th

95 d in peripheral blood mononuclear cells from hematopoietic stem-cell transplant (HSCT) and solid orga

96 In five pairs, hematopoietic stem-cell transplant (HSCT) donors were se

97 representing 664 admissions for induction or hematopoietic stem-cell transplant (HSCT) from 2006 to 2

98 alovirus (CMV) infection in adult allogeneic hematopoietic stem-cell transplant (HSCT) patients.

99 plant recipients, the risk of skin cancer in hematopoietic stem-cell transplant (HSCT) recipients has

100 Among hematopoietic stem-cell transplant (HSCT) recipients, cy

101 the prevention of CMV disease in allogeneic hematopoietic stem-cell transplant (HSCT) recipients.

102 alovirus (CMV) morbidity and mortality after hematopoietic stem cell transplants (HSCTs) are currentl

103 ted in 2 phase 1 studies among recipients of hematopoietic stem cell transplants (HSCTs).

104 gh-throughput integration site analysis in a hematopoietic stem cell-transplanted humanized mouse mod

105 Hematopoietic stem cell transplant, if performed early i

106 rt describes results of related or unrelated hematopoietic stem-cell transplants in 111 patients with

107 KIR/HLA mismatched hematopoietic stem cell transplants induce alloreactive

108 The role of allogeneic hematopoietic stem cell transplant is less clear but may

109 Twenty-two (58%) had received an allogeneic hematopoietic stem cell transplant (median, 61 [interqua

110 tio, 3.81; 95% CI, 2.39-6.07) and autologous hematopoietic stem cell transplant (odds ratio, 1.28; 95

111 odds of in-hospital mortality in allogeneic hematopoietic stem cell transplant (odds ratio, 3.81; 95

112 otherapy given as a conditioning regimen for hematopoietic stem-cell transplant or myeloablative dose

113 age (P = .047), the conditioning regimen for hematopoietic stem cell transplant (P = .002), and the c

114 case of fatal mycosis in a nonmyeloablative hematopoietic stem cell transplant patient, we identifie

115 ed seven organ transplant recipients and one hematopoietic stem-cell transplant patient with positive

116 Following immune reconstitution, hematopoietic stem cell transplant patients often displa

117 itumor T cells, we infused 12 haploidentical hematopoietic stem cell transplant patients with increas

118 illosis (IPA) is frequent and often fatal in hematopoietic stem cell transplant patients.

119 g-term survivors of myeloablative allogeneic hematopoietic stem cell transplant patients.

120 he congenital setting and in solid-organ and hematopoietic stem cell transplant patients.

121 nificantly higher odds of mortality than non-hematopoietic stem cell transplant patients.

122 recipients was significantly higher than non-hematopoietic stem cell transplant patients.

123 Among patients with hematopoietic stem cell transplant, persons with autolog

124 ric leukemia, myelodysplastic syndromes, and hematopoietic stem cell transplant populations has been

125 CD45 antibody has been added to conventional hematopoietic stem cell transplant preparative regimens

126 with refractory neuroblastoma (16 with prior hematopoietic stem cell transplant) received a median ac

127 A case of Legionnaires' disease in a hematopoietic stem cell transplant recipient caused by t

128 za A(H1N1)pdm09 infection was diagnosed in a hematopoietic stem cell transplant recipient during cond

129 nfection and acute liver failure in an adult hematopoietic stem cell transplant recipient.

130 lant cohort, which was similar to autologous hematopoietic stem cell transplant recipients (30.1%) an

131 Autologous hematopoietic stem cell transplant recipients and those

132 Hematopoietic stem cell transplant recipients are more l

133 Hematopoietic stem cell transplant recipients are more l

134 e, approximately 20% of pediatric allogeneic hematopoietic stem cell transplant recipients develop di

135 e of ribavirin in preventing RSV LRTIs in 50 hematopoietic stem cell transplant recipients or patient

136 Five hematopoietic stem cell transplant recipients that devel

137 The frequency of severe sepsis in hematopoietic stem cell transplant recipients was five t

138 Twenty-four hematopoietic stem cell transplant recipients were enrol

139 syndrome on induction therapy or allogeneic hematopoietic stem cell transplant recipients were rando

140 31 human pancreata obtained at autopsy from hematopoietic stem cell transplant recipients who had re

141 a retrospective cohort of female allogeneic hematopoietic stem cell transplant recipients who receiv

142 This study shows that survival rate of hematopoietic stem cell transplant recipients with diffu

143 ave reported mortality rates of about 80% in hematopoietic stem cell transplant recipients with diffu

144 Similarly, in subsequent admissions, hematopoietic stem cell transplant recipients with graft

145 We compared outcomes of hematopoietic stem cell transplant recipients with sever

146 A total of 21,898 hematopoietic stem cell transplant recipients with sever

147 In allogeneic hematopoietic stem cell transplant recipients, restorati

148 ents, and is a leading cause of mortality in hematopoietic stem cell transplant recipients.

149 virus infection causing diarrhea among adult hematopoietic stem cell transplant recipients.

150 ssociated with mortality of severe sepsis in hematopoietic stem cell transplant recipients.

151 sease (IBD), and poor survival in allogeneic hematopoietic stem cell transplant recipients.

152 ion, Clinical Modification codes to identify hematopoietic stem cell transplant recipients.

153 nce the risk of invasive aspergillosis among hematopoietic stem cell transplant recipients.

154 ific T cells and viral control in allogeneic hematopoietic stem cell transplant recipients.

155 ients with hematological malignancies and in hematopoietic stem cell transplant recipients.

156 n the clinical management of solid organ and hematopoietic stem cell transplant recipients.

157 Allogeneic hematopoietic stem-cell transplant recipients often rece

158 Immune reconstitution of autologous hematopoietic stem-cell transplant recipients with the p

159 munity in healthy seropositive donors and in hematopoietic stem-cell transplant recipients.

160 Sixteen (73%) of the illnesses occurred in hematopoietic stem-cell transplant recipients.

161 versus-host disease (cGVHD) after allogeneic hematopoietic stem cell transplant reflects a complex im

162 for patients with JMML relies on allogeneic hematopoietic stem cell transplant, relapse is the most

163 a on recipients of allogeneic and autologous hematopoietic stem cell transplants, respectively.

164 Hematopoietic stem cell transplant (SCT) is currently th

165 infection that occurred among 64 allogeneic hematopoietic stem cell transplant (SCT) recipients in a

166 studied 53 patients that received allogeneic hematopoietic stem cell transplants (SCT) between 1999 a

167 Previous studies of recipients of hematopoietic stem-cell transplants suggest that graft-v

168 Hematopoietic stem cell transplant therapy is limited by

169 ration that siRNAs can be used together with hematopoietic stem cell transplant to stably modulate ge

170 se from self-renewing stem cells, and single hematopoietic stem-cell transplants to show clonality.

171 Allogeneic hematopoietic stem cell transplant was offered to select

172 A retrospective review of 383 consecutive hematopoietic stem-cell transplants was performed with a

173 (n = 6) or allogeneic adult sibling (n = 5) hematopoietic stem cell transplants were studied.

174 Twenty-one recipients of allogeneic hematopoietic stem cell transplants who underwent GBCA-e

175 Six patients were recipients of allogeneic hematopoietic stem cell transplant, with their infection